ERS Research Seminar
Use of biologics in adults/adolescents with severe corticosteroid refractory asthma and setting a future research agenda
13 – 14 April 2018 – London, UK

Day 1 - Friday, 13 April 2018
Chair: Stephen Holgate

08:45 – 09:00  Registration
09:00 – 09:10  Welcome and introduction to Day 1

Session I: Severe asthma - current knowledge
09:10 – 09:40  Cellular and molecular phenotyping (endotyping) in severe asthma (Peter Sterk, NL)
09:40 – 10:10  Biologics for severe T2 asthma: review of licensed and pipeline therapies (Stephanie Korn, DE)
10:10 – 10:40  How can we apply new evidence on biomarkers to care pathways for severe asthma? (Guy Brusselle, BE)
10:40 – 11:10  General discussion
11:10 – 11:30  Coffee break

Session II: Challenges for clinical development
11:30 – 12:00  Key challenges faced during clinical development of biologics for severe asthma –
Six short oral presentations (3 PowerPoint slides each)
12:00 – 12:30  General discussion
12:30 – 13:30  Lunch break

13:30 – 17:15 Session III: Break out Session: What is this Seminar's position on use of biologics in severe refractory asthma? (Four breakout working groups – 45 min per each session)

13:30 – 13:45  Explain tasks and operating methods
13:45 – 14:30  Session 1: Identifying clinically relevant phenotypes/endotypes: what do these patients look like in practice?

Question 1 – What are the clinical characteristics of severe asthmatics who are candidates for anti-IgE therapy?
Question 2 – What are the clinical characteristics of severe asthmatics who are candidates for anti-IL5 therapy?
Question 3 – What are the clinical characteristics of severe asthmatics who are candidates for anti-IL4R therapy?

Each group will have to answer the question: Is there a possible prioritization for biologic use in severe allergic asthma with elevated eosinophil count?
14:30 – 15:15  **Session 2**: How do we treat patients with severe refractory asthma? Can a realistic aim of the biologic era be to consign OCS to the past?

**Question 4** – What are the morbidity and clinical outcomes of severe asthmatics treated with long-term oral corticosteroids (OCS)?

**Question 5** – What is the best timing for biologic use in severe asthma? Early intervention?

**Question 6** – When do we consider bronchial thermoplasty in the era of biologics?

15:15 – 15:45  **Coffee break**

15:45 – 16:30  **Session 3**: What monitoring is necessary, how should these patients be followed up, and how can we determine response to treatment?

**Question 7** – What are the treatment goals in severe refractory asthma? (are they the same with all biologics or are they biologic-specific?)

**Question 8** – Have we got clear stopping rules for all biologics in severe refractory asthma?

**Question 9** – How do we monitor safety of biologics?

16:30 – 17:15  Round table: Report back from outbreak session

**Day 2 - Saturday, 14 April 2018**

**Chairs**: Roland Buhl, Marc Humbert

09:00 – 09:30  Summary of Day 1 and possible outputs, next steps and plenary discussion

09:30 – 09:40  Objectives of the day and methods of working

09:40 – 10:00  Brief description of SHARP ERS Clinical Research Collaborative (Ratko Djukanovik, UK)

**Session IV: Looking forward; evidence gaps, new challenges and opportunities in severe asthma**

10:00 – 10:20  Non-T2 severe asthma; knowns, known unknowns and unknown unknowns (Elisabeth Bel, NL)

10:20 – 10:40  What should we be trying to achieve; the patients’ viewpoint (Dominique Hamerlijnck, NL)

10:40 – 11.00  How can new technologies be harnessed to improve the lives of people with severe asthma? (Samantha Walker, UK)

11:00 – 11:30  General discussion

11:30 – 11:50  **Coffee break**

11:50 – 15:15  **Session V: Break out Session**: Developing a roadmap to meet the future challenges of severe asthma? (Four breakout working groups – 30 min per each session)

11:50 – 12:00  Explain the aims, objectives, method of working and potential outputs for the Work Groups

12:00 – 12:30  **Session 1**: Setting a new research agenda for severe asthma

**Question 1** – What are the key areas for new research in adults and young people?

**Question 2** – Can these research themes be prioritised?

**Question 3** – What opportunities for high quality research can be harnessed in Europe (and beyond)?
12:30 – 13:00  **Session 2**: What and who is needed to deliver this new research and by whom?

*Question 4* – Are there new models and funding opportunities for conducting this research?
*Question 5* – How can we best galvanise the research community to take on these challenges?
*Question 6* – What is the role of industry in such initiatives?
*Question 7* – What are the expectations and potential outputs to maximise upon impact on the care pathways?

13:00 – 14:00  *Lunch break*

14:00 – 14:30  **Session 3**: What are the hurdles to be overcome and formulation of a delivery plan?

*Question 8* – What might a 5-10 year Severe Asthma Research Roadmap look like?
*Question 9* – How can SHARP be operationalised to develop and deliver these aspirations?
*Question 10* – Are there international and other opportunities that can brought into the Roadmap?

14:30 – 15:15  **Round table**: Report back from outbreak session

15:15 – 15:30  **Concluding comments and next steps** – Seminar and SHARP Steering Committees (Stephen Holgate, Roland Buhl, Marc Humbert, Ratko Djukanovic, Elisabeth Bel and Dominique Hamerlijnck)